폐렴 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장 및 동향 예측(2024-2032년)

The global demand for Pneumonia Therapeutics Market is presumed to reach the market size of nearly USD 8.96 Billion by 2032 from USD 4.44 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Pneumonia therapeutics refers to the medical treatments and interventions aimed at addressing pneumonia, an inflammatory lung condition typically caused by bacterial, viral, or fungal infections. Therapeutic approaches may include antibiotics, antiviral medications, supportive care, and, in severe cases, hospitalization. The goal is to eliminate the causative agent, alleviate symptoms, and promote respiratory recovery, ensuring optimal patient outcomes.

MARKET DYNAMICS

The Pneumonia therapeutics market is influenced by factors such as the high prevalence of respiratory infections, increasing aging populations, and the persistence of pneumonia-related complications. Rising awareness and early diagnosis of pneumonia, coupled with advancements in therapeutic options, contribute to the market's growth. The demand for effective and targeted treatment options, including antibiotics and vaccines, plays a crucial role in driving the market. Additionally, the impact of infectious disease outbreaks, such as the COVID-19 pandemic, highlights the importance of pneumonia therapeutics and respiratory health. Ongoing research and development efforts focusing on novel treatment modalities and personalized medicine also contribute to the expansion of the pneumonia therapeutics market.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pneumonia therapeutics. The growth and trends of Pneumonia Therapeutics Industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the pneumonia therapeutics market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Bacterial Pneumonia
• Viral Pneumonia
• Fungal Pneumonia

By Age Group

• Children
• Adult
• Geriatric

By Route Of Administration

• Oral
• Parenteral
• Others

By Drug Class

• Antibiotics
• Antiviral Drugs
• Antifungal Drugs
• Corticosteroids
• Others (NSAIDs, Cough Suppressant, Etc.)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pneumonia Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pneumonia therapeutics market include AstraZeneca, Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lupin Pharmaceuticals, Inc., Innoviva, Inc., Wockhardt Ltd., Sumitomo Pharma Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PNEUMONIA THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Age Group
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Drug Class
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY TYPE

• 5.1 Overview by Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type
• 5.4 Bacterial Pneumonia Historic and Forecast Sales by Regions
• 5.5 Viral Pneumonia Historic and Forecast Sales by Regions
• 5.6 Fungal Pneumonia Historic and Forecast Sales by Regions

6 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

• 6.1 Overview by Age Group
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Age Group
• 6.4 Children Historic and Forecast Sales by Regions
• 6.5 Adult Historic and Forecast Sales by Regions
• 6.6 Geriatric Historic and Forecast Sales by Regions

7 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1 Overview by Route of Administration
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Route of Administration
• 7.4 Oral Historic and Forecast Sales by Regions
• 7.5 Parenteral Historic and Forecast Sales by Regions
• 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

• 8.1 Overview by Drug Class
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Drug Class
• 8.4 Antibiotics Historic and Forecast Sales by Regions
• 8.5 Antiviral Drugs Historic and Forecast Sales by Regions
• 8.6 Antifungal Drugs Historic and Forecast Sales by Regions
• 8.7 Corticosteroids Historic and Forecast Sales by Regions
• 8.8 Others (NSAIDs, Cough suppressant, etc.) Historic and Forecast Sales by Regions

9 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1 Overview by Distribution Channel
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Distribution Channel
• 9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 9.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 9.6 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. South East Asia Sales Analysis
  • 10.5.10. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE PNEUMONIA THERAPEUTICS COMPANIES

• 11.1. Pneumonia Therapeutics Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF PNEUMONIA THERAPEUTICS INDUSTRY

• 12.1. Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. AstraZeneca
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. Novartis AG
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. AbbVie Inc.
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. Teva Pharmaceutical Industries Ltd.
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. Pfizer Inc.
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. Sanofi
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. Lupin Pharmaceuticals Inc.
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. Innoviva Inc.
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments
• 12.11. Wockhardt Ltd.
  • 12.11.1. Company Overview
  • 12.11.2. Company Revenue
  • 12.11.3. Products
  • 12.11.4. Recent Developments
• 12.12. Sumitomo Pharma Co. Ltd.
  • 12.12.1. Company Overview
  • 12.12.2. Company Revenue
  • 12.12.3. Products
  • 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies